Reema Goel1, William Moore1, Baran Sumer2, Saad Khan3, David Sher4, Rathan M Subramaniam1,5,6,7. 1. 1 Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9140. 2. 2 Department of Otolaryngology and Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, TX. 3. 3 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 4. 4 Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX. 5. 5 Advanced Imaging Research Institute, University of Texas Southwestern Medical Center, Dallas, TX. 6. 6 Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. 7. 7 Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
OBJECTIVE: The purpose of this article is to summarize the evidence for the value of PET/CT for the management of patients with head and neck squamous cell cancer and suggest best clinical practices. CONCLUSION: FDG PET/CT is a valuable imaging tool for identifying unknown primary tumors in patients with known cervical node metastases leading to management change and is the standard of care for the initial staging of stage III and IV head and neck squamous cell carcinomas (HNSCCs), for assessing therapy response when performed at least 12 weeks after chemoradiation therapy, and for avoiding unnecessary planned neck dissection. Neck dissection is avoided if PET/CT findings are negative-regardless of the size of the residual neck nodes-because survival outcomes are not compromised. FDG PET/CT is valuable in detecting recurrences and metastases during follow-up when suspected because of clinical symptoms and serves as a prognostic marker for patient survival outcomes, for 5 years. Using FDG PET/CT for routine surveillance of HNSCC after 6 months of treatment without any clinical suspicion should be discouraged.
OBJECTIVE: The purpose of this article is to summarize the evidence for the value of PET/CT for the management of patients with head and neck squamous cell cancer and suggest best clinical practices. CONCLUSION: FDG PET/CT is a valuable imaging tool for identifying unknown primary tumors in patients with known cervical node metastases leading to management change and is the standard of care for the initial staging of stage III and IV head and neck squamous cell carcinomas (HNSCCs), for assessing therapy response when performed at least 12 weeks after chemoradiation therapy, and for avoiding unnecessary planned neck dissection. Neck dissection is avoided if PET/CT findings are negative-regardless of the size of the residual neck nodes-because survival outcomes are not compromised. FDG PET/CT is valuable in detecting recurrences and metastases during follow-up when suspected because of clinical symptoms and serves as a prognostic marker for patient survival outcomes, for 5 years. Using FDG PET/CT for routine surveillance of HNSCC after 6 months of treatment without any clinical suspicion should be discouraged.
Entities:
Keywords:
FDG PET/CT; diagnosis; follow-up; head and neck cancer; head and neck squamous cell cancer; head and neck squamous cell carcinoma (HNSCC); recurrence detection; staging; therapy assessment
Authors: Krystle A Lang Kuhs; C Burton Wood; Jamie Wiggleton; Joseph M Aulino; Brian Latimer; Derek K Smith; Noemi Bender; Sarah Rohde; Kyle Mannion; Young Kim; Robert Sinard; Alexander Langerman; Arthur Fleischer; Carole Fakhry; Tim Waterboer; James L Netterville Journal: Cancer Date: 2020-03-04 Impact factor: 6.860
Authors: L D Patel; K Bridgham; J Ciriello; R Almardawi; J Leon; J Hostetter; S Yazbek; P Raghavan Journal: AJNR Am J Neuroradiol Date: 2022-02-17 Impact factor: 3.825
Authors: Mohamed A Naser; Kareem A Wahid; Abdallah S R Mohamed; Moamen Abobakr Abdelaal; Renjie He; Cem Dede; Lisanne V van Dijk; Clifton D Fuller Journal: Head Neck Tumor Segm Chall (2021) Date: 2022-03-13
Authors: P Wangaryattawanich; B F Branstetter; J D Ly; U Duvvuri; D E Heron; T J Rath Journal: AJNR Am J Neuroradiol Date: 2020-05-28 Impact factor: 3.825